A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.
AG120-C-001
Phase 1 other active
Quick answer
A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation. for AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation. is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.
- Phase
- Phase 1
- Modality
- other
- Status
- active